• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market

    5/22/25 7:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email

    SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company's silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market.

    SINTX remains focused on advancing silicon nitride technologies for medical applications; however, the material's broad utility allows for selective expansion into high-impact adjacent sectors. In line with this strategic expansion, the Company has formed a wholly-owned subsidiary that will have a dedicated management team focused on developing and commercializing agricultural and environmental technologies—signaling the official launch of SINTX Agribiotech, Inc.

    Market Opportunity

    The global antimicrobial fertilizer and crop protection market is projected to grow significantly, reaching up to $10.36 billion by 2030. SINTX intends to position its Si₃N₄ technology at the intersection of sustainability and high-performance crop protection within an industry increasingly focused on sustainable, eco-friendly solutions.

    Independent Path for Growth

    The new agribiotech subsidiary will operate independently from SINTX's medical device business, with its own development pipeline. This separation allows for focused resource allocation, technology validation in field settings, and potential partnerships or licensing opportunities with agricultural companies.

    "This is more than diversification—it's about unlocking the full potential of our core material," said Eric Olson. "We're establishing a clear path to deploy our Si₃N₄ into vineyards, orchards, farmlands and hydroponic facilities, potentially beginning with one of the most compelling use cases: wine production."

    Silicon Nitride: A Natural Defense Against Crop Disease

    Internal research previously published in Frontiers in Microbiology demonstrates that silicon nitride provides powerful antifungal protection against Plasmopara viticola, the pathogen responsible for grapevine downy mildew, one of the most devastating diseases affecting vineyards globally. The study demonstrated that treating grapevine varieties such as Cabernet Sauvignon and Cannonau with Si₃N₄ reduced the growth and sporulation of P. viticola by 80–90%, with complete protection observed in select trials.

    Unlike traditional fungicides, SINTX's Si₃N₄ formulation offers broad-spectrum antimicrobial action without damaging plant tissue or the surrounding environment—especially relevant as copper-based fungicides face increasing regulatory restrictions. (see: Frontiers in Microbiology, 2021)

    "Silicon nitride doesn't just inactivate pathogens—it can also prevent most infections altogether," said Eric Olson, Chairman and CEO of SINTX. "In our recent studies, silicon nitride exhibited no phytotoxicity, helped buffer environmental pH, and showed no evidence of cytotoxicity in humans. It's a sustainable, high-performance alternative to copper and chemical-based treatments in viticulture."

    For more information about SINTX Agribiotech or silicon nitride applications in medical or agriculture applications, please visit www.sintx.com.

    About SINTX Technologies, Inc.

    Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods.

    Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Forward looking statements include our belief that Si₃N₄ will be a sustainable, high-performance alternative to copper and chemical-based treatments in viticulture, our ability to position silicon nitride technology at the intersection of sustainability and high-performance crop protection , and our ability to eventually develop an effective crop protection product and successfully market such a product. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.

    Business and Media Inquiries for SINTX:

    SINTX Technologies

    801.839.3502

    [email protected]



    Primary Logo

    Get the next $SINT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market

      SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company's silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market. SINTX remains focused on advancing silicon nitride technologies for medical applications; however, the material's broad utility allows for sel

      5/22/25 7:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization

      Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT), an advanced ceramics company pioneering medical and antipathogenic applications of silicon nitride (Si₃N₄), today provided a comprehensive update on its operational progress, strategic initiatives, and financial position for the first quarter ended March 31, 2025. "We are executing a disciplined transformation that aligns our core capabilities in advanced ceramics with fast-growing, high-impact healthcare applications. This transition positions us for sustainable value creation," said Eric K. Olson, CEO and President of SINTX Technologies. Refocusing on High-Growth Medical Markets SINTX has ac

      5/15/25 7:05:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Announces Strategic Changes to Board of Directors

      Company positions for long-term growth in medical device markets Salt Lake City, UT, April 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT), an advanced ceramics company focused on medical device applications, today announced changes to its Board of Directors. The updates reflect the Company's ongoing strategic transformation into a focused medical technology business. Key changes include the retirement of longtime Chairman Dr. B. Sonny Bal, the appointment of President and CEO Eric Olson as Chairman of the Board, and the addition of five new directors with decades of industry expertise spanning orthopedics, spine, interventional pain, cardiovascular, medical device bu

      4/3/25 8:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Mark Lewis bought $11,800 worth of shares (5,000 units at $2.36) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/14/25 7:00:09 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • Chief Strategy Officer Honigblum Gregg R. bought $7,160 worth of shares (4,000 units at $1.79), increasing direct ownership by 40% to 14,000 units (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/1/25 6:10:49 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • President and CEO Olson Eric K. bought $28,088 worth of shares (14,500 units at $1.94) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      4/30/25 2:25:41 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Leadership Updates

    Live Leadership Updates

    See more
    • SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

      Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

      11/19/24 6:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

      SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

      11/14/24 7:25:52 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SiNtx Technologies Inc.

      SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

      4/1/24 4:17:43 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

      SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

      2/13/24 8:12:54 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    SEC Filings

    See more
    • SiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sintx Technologies, Inc. (0001269026) (Filer)

      5/22/25 7:15:34 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SiNtx Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sintx Technologies, Inc. (0001269026) (Filer)

      5/15/25 7:10:20 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by SiNtx Technologies Inc.

      10-Q - Sintx Technologies, Inc. (0001269026) (Filer)

      5/15/25 7:00:27 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Mark Lewis bought $11,800 worth of shares (5,000 units at $2.36) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/14/25 7:00:09 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • Chief Strategy Officer Honigblum Gregg R. bought $7,160 worth of shares (4,000 units at $1.79), increasing direct ownership by 40% to 14,000 units (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/1/25 6:10:49 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • President and CEO Olson Eric K. bought $28,088 worth of shares (14,500 units at $1.94) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      4/30/25 2:25:41 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Financials

    Live finance-specific insights

    See more
    • SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

      The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

      7/6/22 9:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Issues 2022 10-K and Announces Investor Conference Call

      SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced today the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission. In 2021, SINTX made significant investments into the expansion of its three priority business segments - biomedical, industrial/armor, and antipathogenic - through the purchase of new technology, equipment, and personnel. The Company is narrowly focused on opportunities closest to revenue such as armor materials and plates, the development of new biomedi

      3/25/22 5:41:39 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

      SALT LAKE CITY, June 30, 2021 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced today it has moved into the next phase of its relationship with O2TODAY and sold the first shipment of FleX SN-AP antipathogenic silicon nitride powder to O2TODAY for integration into a proprietary line of masks and filters. "O2TODAY announced on its website today that it is taking limited pre-orders for masks and mask filters integrated with SINTX's antipathogenic powder," said Dr. Sonny Bal, President and CEO at SINTX Technologies. "We share th

      6/30/21 9:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care